NeOnc to Present NEO100 and NEO212 Data at Neuro-Oncology Meeting

What happened

NeOnc Technologies Holdings plans to present two posters at the Society for Neuro-Oncology’s annual meeting in Philadelphia on November 13, 2026. One will report updated NEO100 results from a Phase 1/2a study and compassionate use; the other will cover Phase 1 safety, drug movement through the body, and early activity signals for NEO212.

Confirmed

Global impact / market context

The presentations may give investors new information about progress in NeOnc’s two investigational drug programs, including safety and early signs of activity. Any stronger evidence could influence expectations for future development, while the company says neither treatment’s safety nor its effectiveness has been established.

Analyst inference

The update concerns early-stage research, not an approved treatment or a confirmed commercial product. NEO100 is being studied for recurrent IDH1-mutant astrocytoma, while NEO212 research includes recurrent, treatment-resistant brain cancer and brain metastases; results could shape later development decisions and related spending.

Analyst inference

What to watch

1. Review the NEO100 poster for the updated Phase 1/2a and compassionate-use findings in recurrent IDH1-mutant astrocytoma, while noting the article provides no outcome details. Confirmed
2. Check the NEO212 poster for Phase 1 safety, drug movement through the body, and early activity signals in treatment-resistant recurrent GBM and brain metastases. Confirmed
3. Assess whether the presented findings support further studies; any additional trial plans, costs, or timelines remain unknown in the supplied article and should not be assumed. Analyst inference

Evidence

• Original source link unavailable